Advertisement
Letter to the Editor| Volume 150, P130-132, June 2021

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma

Published:April 23, 2021DOI:https://doi.org/10.1016/j.ejca.2021.03.022
Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma
Previous ArticleNew cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown
Next ArticleLenvatinib and osteonecrosis of the jaw: A pharmacovigilance study
      Xeroderma pigmentosum (XP) is an autosomal recessive disorder characterised by deficient nucleotide excision repair (NER) of ultraviolet-induced DNA damage resulting in an increased skin carcinogenesis [
      • Lehmann A.R.
      • et al.
      Xeroderma pigmentosum.
      Orphanet J Rare Dis. 2011; 6: 70
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Lehmann A.R.
        • et al.
        Xeroderma pigmentosum.
        Orphanet J Rare Dis. 2011; 6: 70
        View in Article
        • Deinlein T.
        • et al.
        Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature.
        Eur J Canc. 2017; 83: 99-102
        View in Article
        • Hauschild A.
        • et al.
        Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
        Eur J Canc. 2017; 77: 84-87
        View in Article
        • Momen S.
        • et al.
        Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
        Cold Spring Harb Mol Case Stud. 2019; 5
        View in Article
        • Hong W.J.
        • et al.
        Angiosarcoma arising on the scalp in a Korean patient with xeroderma pigmentosum variant type.
        Photodermatol Photoimmunol Photomed. 2018; 34: 343-346
        View in Article
        • De Silva B.D.
        • et al.
        Angiosarcoma of the head and neck associated with xeroderma pigmentosum variant.
        Br J Dermatol. 1999; 141: 166-167
        View in Article
        • D'Angelo S.P.
        • et al.
        A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401).
        Lancet Oncol. 2018; 19: 416-426
        View in Article
        • Mehnert J.M.
        • et al.
        Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
        J Clin Invest. 2016; 126: 2334-2340
        View in Article
        • Soura E.
        • et al.
        Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
        Pediatr Dermatol. 2018; 35: e334-e336
        View in Article

      Article info

      Publication history

      Published online: April 23, 2021
      Accepted: March 12, 2021
      Received: March 5, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2021.03.022

      Copyright

      © 2021 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX